Evidence for a common mechanism of SIRT1 regulation by allosteric activators.
Level 5 - mechanism / opinion, no new human data
In vitro biochemical and primary cell mechanistic study without clinical data
PubMed 23471411 · doi:10.1126/science.1231097
What was done
The authors investigated the molecular mechanism of sirtuin-activating compounds (STACs) on SIRT1 deacetylase activity. They examined the role of hydrophobic motifs in natural SIRT1 substrates (PGC-1α and FOXO3a), evaluated the requirement of SIRT1 N-terminal residue Glu230 across multiple STAC chemical scaffolds, and tested the metabolic effects of STACs in primary cells reconstituted with activation-defective SIRT1.
What was found
Specific hydrophobic motifs in SIRT1 substrates facilitate SIRT1 activation by STACs. Residue Glu230 in the N-terminal domain of SIRT1 was found to be critical for activation by all tested STAC scaffolds, including a new class of activators. In primary cells expressing activation-defective SIRT1, the metabolic effects of STACs were blocked. The abstract reports no numerical values, kinetic parameters, or effect sizes.
Why it matters
This study provides evidence for a shared direct allosteric activation mechanism for SIRT1 across diverse chemical scaffolds, addressing debate regarding whether STACs directly target SIRT1.
Limits
Findings are limited to in vitro assays and primary cell models; whole-organism physiology, in vivo pharmacokinetics, and human clinical outcomes were not assessed. The abstract reports no quantitative data, sample sizes, or statistical metrics.
Cited by
- supports David Sinclair's group published a 2013 Science paper identifying the specific amino acid mechanism by which resveratrol directly activates SIRT1.